Research Library
Metabolic Peptide Research: Incretins and Amylin Analogues
The incretin field moved from single-receptor to multi-receptor pharmacology in under a decade. These pages summarise what the published trials actually measured, and what remains unknown.
Guides in this category
RT Research: Triple Receptor Agonism Explained
RT is an investigational triple agonist at the GIP, GLP-1 and glucagon receptors. It is not approved anywhere and Phase 3 outcome and safety data is still accumulating.
Read guide
TZ Research: Dual GIP/GLP-1 Agonism Evidence
TZ is a dual GIP and GLP-1 receptor agonist approved for type 2 diabetes and for chronic weight management in several jurisdictions. It has the most complete trial dataset of the current multi-receptor agents.
Read guide
SM Research: GLP-1 Evidence and Outcomes
SM is a GLP-1 receptor agonist approved for type 2 diabetes, chronic weight management and cardiovascular risk reduction in people with obesity and established cardiovascular disease. The STEP and SELECT programmes gave the class its first hard-outcome evidence, moving it beyond weight and glucose endpoints.
Read guide
Cagrilintide Research: Amylin Analogue Evidence
Cagrilintide is a long-acting amylin analogue investigated alone and in fixed combination with SM (CagriSema). Amylin is a pancreatic hormone co-secreted with insulin that signals satiety through a different route from GLP-1, which is why combining the two is of interest. It is not approved.
Read guide
How Incretin Peptides Work: Mechanisms of Action Explained
Understanding which receptor does what explains why dual and triple agonists outperform single-receptor drugs, and why side-effect profiles differ. This page is a mechanism reference, not a treatment guide.
Read guide
Incretin Side Effects: What the Trial Data Reports
Adverse event data for incretin drugs comes from large randomised trials and from post-marketing surveillance, which answer different questions. Gastrointestinal effects dominate trial data; rarer signals emerge later from real-world reporting. This page summarises what has been reported and how confident the evidence is.
Read guide
Combination Research: Why Multi-Pathway Agents Are Studied
Combination research in metabolic pharmacology means engaging more than one receptor system, either in a single molecule or as co-administered agents. The rationale is that appetite, satiety and energy expenditure are separate physiological levers. This page reviews what has been tested in trials — it is not a protocol page.
Read guide
Other categories
Peptide Research
Mechanisms, study data and limitations for the most-researched peptides.
Longevity
The measurable biology behind ageing: cells, mitochondria, inflammation, biomarkers.
Hormones
Endocrine physiology, how it is measured, and what the studies show.
Research Library
Head-to-head comparisons and clinical trial reviews with primary sources.
Research supply · Independent documentation and customer feedback
Google Reviews
Read the original reviews
Verified Supplier
Peptides Lookup verified
ScamAdviser 100/100
Rated legitimate and safe
SSL Secured
256-bit encrypted checkout
HPLC Verified
Batch COAs on request
3 Shipping Hubs
Germany · USA · China
Discreet Delivery
Temperature-controlled
We accept · Multiple secure payment methods
- Bank Transfer
- Card via Wise
- Card via Monzo
Your next research order
From reading to your next research kit.
Compare compounds and kit sizes, choose your selection, then review delivery and payment details at checkout.
Laboratory research only. Not for human consumption.
Independently checked
ScamAdviser Trust Score: 100/100
ScamAdviser rates regena.app as legitimate and safe. Check the live result yourself.
Tracked worldwide delivery
4–10 business days from tracking. Delivery cost shown at checkout.
Card or bank transfer
Review your total before payment. Payment is confirmed separately.